1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > NeoStem, Inc. - Product Pipeline Review - 2014

NeoStem, Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 45 pages

NeoStem, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘NeoStem, Inc. - Product Pipeline Review - 2014’, provides an overview of the NeoStem, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NeoStem, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NeoStem, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NeoStem, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the NeoStem, Inc.’s pipeline products

Reasons to buy

- Evaluate NeoStem, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NeoStem, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NeoStem, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NeoStem, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NeoStem, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of NeoStem, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

NeoStem, Inc. - Product Pipeline Review - 2014
Table of Contents

NeoStem, Inc. Snapshot 5
NeoStem, Inc. Overview 5
Key Information 5
Key Facts 5
NeoStem, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
NeoStem, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
NeoStem, Inc. - Pipeline Products Glance 13
NeoStem, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
NeoStem, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
NeoStem, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
NeoStem, Inc. - Drug Profiles 18
Cancer Stem Cell Therapy 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Melapuldencel-T 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
AMR-001 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Dendritic Cell Therapy for Renal Cell Carcinoma 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Cell Therapy for CNS, Respiratory, Immunology and Metabolic Disorders 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Mesenchymal Cells for Wound Care 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Stem Cell Therapy for Macular Degeneration and Glaucoma 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Stem Cell Therapy for Osteoporosis and Periodontitis 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Stem Cell Therapy for Radiation Exposure 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Stem Cell Therapy for Sciatic Nerve Regeneration 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Stem Cell Therapy for AMD and Retinitis Pigmentosa 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
NeoStem, Inc. - Pipeline Analysis 31
NeoStem, Inc. - Pipeline Products by Route of Administration 31
NeoStem, Inc. - Pipeline Products by Molecule Type 32
NeoStem, Inc. - Recent Pipeline Updates 33
NeoStem, Inc. - Dormant Projects 42
NeoStem, Inc. - Locations And Subsidiaries 43
Head Office 43
Other Locations and Subsidiaries 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables

NeoStem, Inc., Key Information 5
NeoStem, Inc., Key Facts 5
NeoStem, Inc. - Pipeline by Indication, 2014 8
NeoStem, Inc. - Pipeline by Stage of Development, 2014 9
NeoStem, Inc. - Monotherapy Products in Pipeline, 2014 10
NeoStem, Inc. - Partnered Products in Pipeline, 2014 11
NeoStem, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
NeoStem, Inc. - Phase III, 2014 13
NeoStem, Inc. - Phase II, 2014 14
NeoStem, Inc. - Phase I, 2014 15
NeoStem, Inc. - Preclinical, 2014 16
NeoStem, Inc. - Discovery, 2014 17
NeoStem, Inc. - Pipeline by Route of Administration, 2014 31
NeoStem, Inc. - Pipeline by Molecule Type, 2014 32
NeoStem, Inc. - Recent Pipeline Updates, 2014 33
NeoStem, Inc. - Dormant Developmental Projects,2014 42
NeoStem, Inc., Subsidiaries 43

List of Figures

NeoStem, Inc. - Pipeline by Top 10 Indication, 2014 7
NeoStem, Inc. - Pipeline by Stage of Development, 2014 9
NeoStem, Inc. - Monotherapy Products in Pipeline, 2014 10
NeoStem, Inc. - Partnered Products in Pipeline, 2014 11
NeoStem, Inc. - Pipeline by Top 10 Route of Administration, 2014 31
NeoStem, Inc. - Pipeline by Top 10 Molecule Type, 2014 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glial Cell Line Derived Neurotrophic Factor (Astrocyte ...

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

  • $ 2500
  • Company report
  • October 2016
  • by Global Markets Direct

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, ...

Ageing - Pipeline Review, H2 2016

October 2016 $ 2000

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.